Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750397 · ClinicalTrials.gov registry record
HIV-to-HIV Transplant at MGH
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 13
- Enrollment target
NCT02750397: Completed study, sponsored by Massachusetts General Hospital.
NCT02750397 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02750397 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. HIV+ individuals who receive a solid organ transplant from HIV-uninfected donors will also be followed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-08 |
| Est. Completion | 2025-07-16 |
What the finished NCT02750397 record still lists
NCT02750397 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02750397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02750397 about?
NCT02750397 is a clinical study titled "HIV-to-HIV Transplant at MGH". HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. HIV+ individuals who receive a solid organ transplant from HIV-uninfected donors will also be followed.
What is the current status of trial NCT02750397?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2016-08. Estimated completion is 2025-07-16.
Who is sponsoring clinical trial NCT02750397?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia